Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel in R/R Follicular Lymphoma
NCT06826118Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Best Objective Response Rate at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06826118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826118.